D. Boral Capital Starts Scilex Holding Co. (SCLX) at Buy

D. Boral Capital analyst Jason Kolbert initiates coverage on Scilex Holding Co. (NASDAQ: SCLX) with a Buy rating and a price target of $22.00.

The analyst comments "Scilex Holding Company is trading at a distressed valuation over past controversies, now ancient history. Today, the company has a diverse portfolio of non-opioid pain management and ethical therapeutics, three of which are marketed products. The lead product is ZTlido, a topical lidocaine patch for post-herpetic neuralgia (PHN). We see the potential for expansion into neck and back pain (real-world use), especially as the high dose version is commercialized, we assume in 2028; Elyxyb (oral celecoxib for migraines), here too, with potential expansion to acute pain such as tension headaches, and Gloperba (oral colchicine for gout prophylaxis) with a differentiated profile that allows easy dose titration. We see a gem in the clinical-stage product SEMDEXA (dexamethasone gel, Phase 3 positive for sciatica), which we view as a blockbuster opportunity. We are launching coverage with a Buy rating and $22.00 price target."

For an analyst ratings summary and ratings history on Scilex Holding Co. click here. For more ratings news on Scilex Holding Co. click here.

Shares of Scilex Holding Co. closed at $0.44 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Us Says Israel, Lebanon Agree To Implement Ceasefire - Bloomberg
• Redwire Defense wins $15.9M Army contract for drone systems